GEN Exclusives

More »

GEN News Highlights

More »
Jul 2, 2010

Lee’s Pharmaceutical Negotiates Chinese Rights to FDA-Approved Hypertension Drug from United Therapeutics

  • Lee’s Pharmaceutical negotiated exclusive rights to commercialize and market United Therapeutics’ FDA-approved prostacyclin analogue Remodulin for the treatment of pulmonary arterial hypertension (PAH) in China. Under terms of the deal China-based Lee’s will have responsibility for carrying out any necessary bridging trials and negotiating the regulatory pathway for clearance for the drug in China.

    The FDA- approved formulation of Remodulin is administered as either a continuous subcutaneous or continuous intravenous infusion. United Therapeutics is also carrying out a Phase III trial program evaluating an oral formulation of the Remodulin active ingredient treprostinil using sustained release technology licensed from Supernus Pharmaceuticals. There are currently no oral prostacyclin therapies approved either in the U.S. or Europe, United Therapeutics points out. Regulatory filing of the oral treprostinil will not be before 2012, the company adds.

    Oral treprostinil is separately undergoing Phase II evaluation for use in reducing the frequency and severity of ulcers located on the fingers and toes of scleroderma patients.

    United Therapeutics reported Remodulin-related revenues of $95,769 for the three months of March 2010, up 24.7% on the equivalent quarter of 2009.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »